netFormulary Oxfordshire Clinical Commissioning Group NHS
Formulary  
 Search
 Formulary Chapter 2: Cardiovascular system - Full Chapter
Chapter Links...
 Details...
02.12  Expand sub section  Lipid-regulating drugs
02.12  Expand sub section  Bile acid sequestrants
02.12  Expand sub section  Ezetimibe
02.12  Expand sub section  Fibrates
02.12  Expand sub section  Statins to top
Atorvastatin
View adult BNF View SPC online View childrens BNF
First Choice
Green

Atorvastatin is the first line statin, usually at 20 mg for primary prevention and 40-80 mg for secondary prevention.

See Lipid Modification Guidance.

APCO September 2015.

 
Simvastatin
View adult BNF View SPC online View childrens BNF
Second Choice
Green

For lipid modification, see Lipid Modification Guidance.

NB. Simvastatin 80 mg is not recommended - MHRA warning.

APCO September 2015.

 
Link  MHRA: Interaction and dosing recommendations
Link  MHRA: Simvastatin - dose limitations with concomitant amlodipine or diltiazem
   
Pravastatin
View adult BNF View SPC online View childrens BNF
Third Choice
Green

Pravastatin, up to 40mg, is a third line alternative for primary prevention in patients who cannot take simvastatin or atorvastatin due to interactions.

See Lipid Modification Guidance.

APCO September 2015.

 
   
Rosuvastatin
View adult BNF View SPC online View childrens BNF
Third Choice
Green

Rosuvastatin is a third line option for secondary prevention in patients who cannot take simvastatin or atorvastatin due to interactions.

See Lipid Modification Guidance.

APCO September 2015.

 
Link  Rosuvastatin PrescQIPP review
   
02.12  Expand sub section  Nicotinic acid group
02.12  Expand sub section  Omega-3 fatty acid compounds
02.12  Expand sub section  PCSK9 inhibitors
02.12  Expand sub section  Other lipid modifying agents
 ....
 Non Formulary Items
Fluvastatin

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Simvastatin and Ezetimibe  (Inegy®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Simvastatin and Fenofibrate  (Cholib®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Red: Medicines which should only be prescribed in secondary care by a specialist.  

Amber Continuation

Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred.   

Amber Shared Care Protocol

Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO).   

Green

Green: Medicines which are suitable for initiation and ongoing prescribing within primary care.   

Brown

Brown: Medicines which should only be prescribed in restricted circumstances.  

Black

Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety.  

OCCG Green

not used  

netFormulary